OncLive TV

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Luis E. Raez, MD, discusses how the COVID-19 pandemic has impacted the treatment of patients with lung cancer.

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Kevin Hughes, MD, discusses mutational risk in oncology.

Christopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

Melissa K. Accordino, MD, MS, discusses the utility of liquid biopsies in breast cancer.

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Thomas Herzog, MD, discusses the data that led to the FDA approval of the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab and whose cancer is associated with homologous recombination deficiency–positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.